Surrey Research Park
10 Nugent Road
Guildford GU2 7AF
United Kingdom
44 14 8334 3434
https://angleplc.com
Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 173
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Andrew David William Newland ACA, Meng | Founder, CEO & Executive Director | 264k | N/A | 1961 |
Mr. Ian Francis Griffiths ACA, BA | CFO, Finance Director, Company Secretary & Executive Director | 164k | N/A | 1964 |
Mr. Martin Cooke | Director of Operations & Regulatory Affairs | N/A | N/A | 1969 |
Dr. Karen Miller Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Andrew John Holder | Head of Investor Relations | N/A | N/A | 1968 |
Ms. Anne-Sophie Pailhes-Jimenez | Head of R&D and Senior Director | N/A | N/A | N/A |
Mr. Brett Swansiger | Chief Commercial Officer | N/A | N/A | N/A |
Mr. Nick Claxton | Senior Vice President of Commercial Operations | N/A | N/A | N/A |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.
El ISS Governance QualityScore de ANGLE plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.